Genzyme Transgenics Corporation

Gtc Biotherapeutics, Inc.

Genzyme Corporation

Genzyme Transgenic Corporation

Edward S Cole

Harry M Meade

Paul Ditullio

Nancy Hsiung

William R Dackowski

Jeffrey F Lemontt

Vermuri B Reddy

Paul DiTullio

Cha-Mer Wei

David Tai-Yui Lau

Richard D Purcell, Jr

Richard Douglas

Julie S Denman

This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.

Transgenically produced antithrombin III

Treatments using transgenic goat produced antithrombin III

This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GaINAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.

Transgenically produced Antithrombin III

Methods of isolating components of interest from a milk sample are described. The methods include a step wherein the solubility of at least a portion of the total milk protein is stabilized in such a manner as to allow isolation of the component of interest without significant loss in yield. Kits for stabilizing the solubility of at least a portion of the total milk protein of the milk sample containing the component of interest also are described.

Isolation of components of interest from milk

A replicable expression vector capable, in a transformed host mammallian cell, of expressing a DNA sequence encoding active human TPA which, when expressed in the host cell, yields active TPA which lacks one or more of the TPA-bound N-linked carbohydrate moieties of naturally occurring human TPA.

Human uterine tissue plasminogen activator produced by recombinant DNA

Growing community of inventors

Bolton, MA, United States of America

Edward S Cole